The clinical burden of allergic rhinitis in five Middle Eastern countries: results of the SNAPSHOT program.
Ahmed Al-Digheari, Bassam Mahboub, Hesham Tarraf...
https://pubmed.ncbi.nlm.nih.gov/30473712Actively Recruiting
Phase Not Applicable
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID06427577
Study on the Mechanism of ZhenQiFuZheng in the Treatment of Allergic Rhinitis Based on Intestinal Flora and Metabolites
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2024-12-09
40
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the effects of ZhenQi FuZheng granules on allergic rhinitis, a condition involving nasal inflammation. This research combines clinical studies with laboratory experiments on cells and animals to better understand how the treatment may influence intestinal flora and metabolites. The goal is to see if this treatment can improve immune balance and reduce type 2 inflammation in patients with allergic rhinitis. Participants in this study will take ZhenQi FuZheng granules orally, one bag twice a day, for 4 weeks. The study involves collecting biological samples and questionnaires to analyze changes in nasal inflammatory factors and nasal secretions. The research is sponsored by The First Affiliated Hospital with Nanjing Medical University and focuses on linking clinical outcomes with basic scientific research. During the 12 weeks of follow-up, researchers will assess participants using the Rhinoconjunctivitis Quality of Life Questionnaire and a Visual Analog Score for pain to monitor improvements related to allergic rhinitis symptoms. Participants will be monitored for any changes and effects of the treatment during this period, ensuring detailed collection of data on quality of life and pain levels.
CONDITIONS
Brief Title
Study on the Mechanism of ZhenQiFuZheng in the Treatment of Allergic Rhinitis Based on Intestinal Flora and Metabolites
Who Can Participate
Age: 18Years - 65Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 to 65 years
- Diagnosed with allergic rhinitis at the Department of Otolaryngology of the First Affiliated Hospital of Nanjing Medical University
You will not qualify if you...
- Patients who refuse to provide biological specimens and complete questionnaires
- Patients with nasal diseases other than allergic rhinitis, such as nasal papilloma or nasal malignant tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 4 weeks
Participants take ZhenQi FuZheng granules orally twice a day for 4 weeks.
1 baseline visit and weekly visits during treatment
Follow-up
Duration - Up to 12 weeks
Participants are monitored for outcomes including quality of life and pain for up to 12 weeks after starting treatment.
Periodic follow-up visits up to 12 weeks
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
Actively Recruiting
Loading map...
Research Team
L
Lei Cheng
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Pathogenesis of rhinitis.
A O Eifan, S R Durham
https://pubmed.ncbi.nlm.nih.gov/27434218Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis.
Lei Cheng, Jianjun Chen, Qingling Fu...
https://pubmed.ncbi.nlm.nih.gov/29949830An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011.
X D Wang, M Zheng, H F Lou...
https://pubmed.ncbi.nlm.nih.gov/26948849Protective effects of astragaloside IV against ovalbumin-induced allergic rhinitis are mediated by T-box protein expressed in T cells/GATA-3 and forkhead box protein 3/retinoic acid-related orphan nuclear receptor γt.
Keqiong Li, Yi Chen, Rong Jiang...
https://pubmed.ncbi.nlm.nih.gov/28586019